

## COPD exacerbations · 5: Management

R Rodríguez-Roisin

Thorax 2006;61:535–544. doi: 10.1136/thx.2005.041863

A review of the most relevant evidence based therapeutic options currently available for the management of exacerbations of COPD

Exacerbations of chronic obstructive pulmonary disease (COPD) have a negative effect on patients in terms of mortality,<sup>1,2</sup> health related quality of life, and decline in lung function including huge socioeconomic costs on healthcare resources. Exacerbations commonly result in worsening of gas exchange<sup>3</sup> and pulmonary haemodynamics,<sup>4</sup> and are also predictive of admission to hospital. A British Thoracic Society audit<sup>5</sup> of the hospital care of patients admitted for exacerbations of COPD revealed that 50% of them did not have a documented diagnosis of COPD, standard diagnostic investigations were often not performed, and subsequent interventions known to have a favourable influence on the outcome were not given. A study of the risk of hospital admissions for exacerbations showed a moderate to high prevalence of potentially amenable factors, suggesting that care is currently unsatisfactory.<sup>6</sup> Unsurprisingly, the management and care of many patients with exacerbations follows a “shotgun” approach with all available treatments being used. The “domino” effect of a hospital admission for acute COPD goes beyond the emergency department and creates seasonally major disruptions in hospital management making COPD the “Cinderella” of medicine.<sup>7</sup> Exacerbations of COPD represent one of the major contributors to the clinical load of physicians who, in addition, have access to only a limited therapeutic armamentarium.<sup>8</sup> The poor recognition of COPD exacerbations and insufficient treatment reflects the multidisciplinary heterogeneity of the pathophysiology of exacerbations.

This paper reviews the most relevant evidence based therapeutic options currently available for the appropriate management of exacerbations of COPD. Over the last year the American Thoracic Society (ATS) and the European Respiratory Society (ERS)<sup>9</sup> have reviewed their own guidelines, and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has released its annual update on management.<sup>10</sup> Likewise, the continuing efforts of national respiratory societies to update their recommendations,<sup>11,12</sup> some using robust evidence based tools,<sup>12</sup> and some extensive reviews<sup>13,14</sup> have to be acknowledged. The reader is encouraged to study these documents which offer a more comprehensive insight into the management of COPD exacerbations, a field that is continually evolving.<sup>15</sup>

Early recognition of exacerbations and prompt treatment ameliorate their clinical progress while improving health related quality of life and reducing the risk of hospital admission.<sup>16</sup> By optimising patient-physician understanding of the nature of exacerbations of COPD and the effects of early treatment, the negative influence of the current morbidity and mortality of exacerbations will be minimised.

### DIAGNOSTIC ASSESSMENT AND PATHOPHYSIOLOGY

Irrespective of the definition of exacerbation used,<sup>17</sup> the clinical diagnosis points to an acute clinical worsening that may necessitate a change in regular treatment.<sup>18,19</sup> However, since there is no objective confirmation of the diagnosis of COPD in 50% of patients,<sup>5</sup> one common problem is to know whether the patient has underlying COPD. A typical history of smoking and the presence of cough, sputum, and breathlessness with reduction in breath sounds and wheezing are the usual pointers to a diagnosis of COPD.<sup>20</sup>

A stepwise approach with four components forms the diagnostic assessment. The first step is an appropriate medical history which identifies one or more of the three cardinal symptoms: increased shortness of breath, increased sputum volume, and increased sputum purulence. These symptoms have to be interpreted in the context of other clinical conditions such as disease severity, frequency of previous acute episodes, the presence of co-morbidities (cardiovascular, diabetes, skeletal muscle), and the socioeconomic environment. The second step is a physical examination to identify the principal respiratory signs (rapid and shallow breathing, use of accessory respiratory muscles, paradoxical chest wall motion, wheezing, attenuated or absent breath sounds, hyperresonance on percussion, pursed lip breathing), cardiovascular signs (increased and/or abnormal pulse heart rate, right heart failure, peripheral oedema, haemodynamic instability), and general signs (altered mental status, central cyanosis). The third step involves the recognition of clinical conditions that are often associated with COPD—for example, pulmonary conditions (pneumonia, pneumothorax, pleural effusion, lung cancer, upper airway obstruction, rib fracture), cardiovascular conditions (pulmonary embolism, right/left heart

**Abbreviations:** COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; FEV<sub>1</sub>, forced expiratory volume in 1 second; LABA, long acting inhaled  $\beta_2$  agonist; LABD, long acting bronchodilator; MDI, metered dose inhaler; NIV, non-invasive ventilation; PEF, peak expiratory flow rate; SABA, short acting  $\beta_2$  agonist; SABD, short acting bronchodilator; SAMA, short acting muscarinic antagonist; SaO<sub>2</sub>, arterial oxygen saturation

Correspondence to:  
Professor R Rodríguez-Roisin, Servei de Pneumologia, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain; rororo@clinic.ub.es

Received  
14 September 2005  
Accepted 10 January 2006

failure), and drug related causes (sedatives, narcotics). All the latter are considered complications that easily mimic exacerbations.<sup>18–21</sup> The fourth step includes several standard diagnostic procedures such as arterial blood gas analysis, chest radiography, routine blood tests, ECG, and Gram stain and culture when sputum is purulent. The use of pulse oximetry alone to measure arterial oxygen saturation ( $SpO_2$ ) is only recommended for mild exacerbations. Forced spirometry is of limited usefulness for the management of exacerbations<sup>22</sup> but is mandatory during the recovery or follow up period to confirm the diagnosis of COPD or to monitor further slow improvement. Peak expiratory flow rate (PEFR), used as an alternative measurement of airflow limitation,<sup>23</sup> correlates well with forced expiratory volume in 1 second ( $FEV_1$ ),<sup>24</sup> although the clinical implications of this correlation remain unclear.<sup>22</sup>

Pathologically, exacerbations of COPD are characterised by enhanced airway inflammation and oedema<sup>25–27</sup> and systemic inflammation,<sup>25, 28</sup> resulting in more airflow limitation and gas exchange defects due to further lung mechanical abnormalities and ventilation-perfusion worsening, along with increased oxygen consumption, altered hypoxic vasoconstriction, and systemic (increased cardiac output) and pulmonary (increased pulmonary artery pressure) haemodynamic abnormalities.<sup>3, 29a, 29b</sup> Interestingly, each of these pathophysiological factors that govern gas exchange can be modulated, at least in part, by the currently available pharmacological and non-pharmacological treatments available (fig 1).<sup>3, 30</sup>


## PHARMACOLOGICAL TREATMENT: THE “ABC APPROACH”

This can be called the “ABC approach”, an acronym that reflects the three classes of drugs (**antibiotics, bronchodilators and corticosteroids**) commonly used for exacerbations of COPD (table 1). However, if we consider only the highest levels of evidence,<sup>10</sup> this is only valid for bronchodilators and systemic steroids (see table S1 available online only at <http://www.thoraxjnl.com/supplemental>).

**Table 1** What is known of pharmacological treatment

<b>Bronchodilators</b>
Short acting inhaled bronchodilators
<ul style="list-style-type: none"> <li>● Improve symptoms and <math>FEV_1</math></li> <li>● No differences between different classes</li> <li>● No additional benefit with combinations</li> <li>● No differences between MDI and nebuliser use</li> <li>● Recommend increasing dose and/or frequency of existing classes</li> </ul>
Theophylline
<ul style="list-style-type: none"> <li>● Discrete effects on symptoms and lung function (second line treatment)</li> <li>● Numerous side effects</li> </ul>
<b>Systemic corticosteroids</b>
<ul style="list-style-type: none"> <li>● Improve symptoms, <math>FEV_1</math> and <math>PaO_2</math> in moderate to severe exacerbations</li> <li>● Reduce treatment failure, relapse and length of hospital stay</li> <li>● Induce more side effects (such as hyperglycaemia)</li> </ul>
<b>Antibiotics</b>
<ul style="list-style-type: none"> <li>● Less risk of treatment failure, mortality and sputum purulence in moderate to severe exacerbations</li> <li>● Oral route is preferred and cheaper</li> <li>● Unlikely benefit of short courses of antibiotics in most patients</li> </ul>

$FEV_1$ , forced expiratory volume in 1 second;  $PaO_2$ , arterial oxygen pressure.



**Figure 1** Effect of currently available pharmacological and non-pharmacological options on the pathophysiological factors that govern gas exchange. +, beneficial effect; −, detrimental effect; ±, beneficial-detrimental effects. Reproduced from Rodríguez-Roisin *et al*<sup>30</sup> with permission from Prous Science.

## Bronchodilators

### Inhaled bronchodilators

Short acting inhaled  $\beta_2$  agonists and anticholinergic agents remain the main treatment modality for exacerbations as they reduce symptoms and improve airflow obstruction. Short acting  $\beta_2$  agonists (SABAs) such as salbutamol and terbutaline act by increasing the concentration of cyclic adenosine monophosphate (cAMP),<sup>31</sup> while anticholinergics such as ipratropium and oxitropium bromide are non-selective muscarinic antagonists (SAMAs).<sup>32–33</sup> Although there are no trials of short acting bronchodilator (SABD) agents, their use in the treatment of exacerbations has not been questioned.<sup>33–34</sup> There are three relevant issues related to the use of SABDs during exacerbations: efficacy of the drugs, drug combinations, and the delivery system for inhaled treatment (table 1).<sup>12</sup>

There is no evidence of a difference between classes of SABDs in terms of bronchodilatation (increased  $FEV_1$  range 150–250 ml) at 90 minutes.<sup>35–37</sup> When inhaled, the effects of SABAs begin within 5 minutes with maximum peaks at 30 minutes; ipratropium begins to take effect after 10–15 minutes with a peak at 30–60 minutes. The effects of the two classes of SABDs decline after 2–3 hours and can last as long as 4–6 hours, depending on their individual properties.<sup>14</sup> Compared with a 54  $\mu$ g ipratropium bromide metered dose inhaler (MDI), a 1.95 mg MDI of metaproterenol sulfate decreased arterial oxygen tension ( $PaO_2$ ) by 0.8 kPa (6 mm Hg) at 20 minutes with minor clinical and functional consequences.<sup>35</sup> Similarly, a 200  $\mu$ g oxitropium bromide MDI did not induce oxygen desaturation at 30 minutes in a randomised controlled trial (RCT) in outpatients.<sup>38</sup> Inspiratory capacity also increased significantly at 30 and 90 minutes after nebulised salbutamol 5.0 mg (approximately by 10% each) in inpatients,<sup>39</sup> suggesting a complementary benefit on acute-on-chronic air trapping and lung hyperinflation,<sup>40–41</sup> a finding with added value in lung function assessment.

By contrast, the efficacy of combinations of SABDs remains unsettled. Unlike stable COPD where the simultaneous concurrent administration of SABDs is more efficacious than either agent given alone,<sup>42</sup> a combination of SABDs given sequentially in exacerbations does not provide additional benefit.<sup>35–43–44</sup>

A systematic review of the route of delivery of SABDs found no significant differences in  $FEV_1$  between the use of hand held MDIs with a good inhaler technique (with or without a spacer device) and nebulisers.<sup>45</sup> A nebuliser with a mouthpiece to avoid nasal deposition or a face mask to avoid ocular side effects with SAMAs is more convenient for sicker patients who usually need admission to hospital and may be more beneficial due to their individual physical properties. However, its effects on mucus viscosity are unknown. As a

rule of thumb, an MDI is more convenient for low doses of SABDs.

Increasing the dose and/or the frequency of existing SABD treatment with SABAs is the strategy recommended by the ATS/ERS<sup>9</sup> and GOLD<sup>10</sup> guidelines. The addition of a SAMA if the clinical response is not immediately favourable is also recommended, despite the uncertainties about combinations of SABDs in this setting.<sup>10</sup> The ATS/ERS guidelines<sup>9</sup> and NICE report<sup>12</sup> recommend the use of SABAs and/or SAMAs. It is most likely, however, that the correct strategy for the physician remains, at least in part, empirical.

Formoterol, a rapid onset long acting inhaled  $\beta_2$  agonist (LABA), previously used as an as-needed reliever in both stable and acute asthma<sup>46</sup> and in exacerbations of COPD without major adverse effects,<sup>47</sup> has also been proposed in a cumulative manner for the management of exacerbations.<sup>48</sup> Despite the fact that high doses of formoterol are well tolerated, it remains uncertain whether this dosage and agent can be used as an alternative to SABDs during exacerbations.<sup>49</sup> Compared with placebo, the LABA salmeterol given via an MDI or dry powdered 50  $\mu\text{g}$  twice daily had a similar cardiovascular safety profile in stable COPD.<sup>50</sup>

There is accumulating evidence that SABAs may increase the risk of adverse cardiovascular events in patients with obstructive airway disease, a finding of special concern for those patients with underlying cardiovascular co-morbidities.<sup>51</sup> However, neither SABAs in any form nor at first time use increased the risk of acute myocardial infarction in a cohort of more than 10 000 patients newly diagnosed with COPD, with and without pre-existing concomitant cardiovascular disease.<sup>52</sup> Troublesome muscular tremor, hypokalaemia, and increased oxygen consumption also occur. Subclinical mild deterioration in gas exchange within 30–90 minutes of nebulisation with further hypoxaemia and/or increased alveolar-to-arterial oxygen difference and moderately increased cardiac output are frequent events.<sup>53</sup> The main adverse effect of SAMAs is mouth dryness, sometimes associated with a bitter taste and occasional prostatic symptoms.

The ATS/ERS guidelines<sup>9</sup> recommend adding long acting bronchodilators (LABDs) and inhaled steroids as an adjunct to the treatment if patients were not using them, although there is no evidence for such a recommendation. Currently, the maintenance or addition of salmeterol during an exacerbation needs to be considered on an individual basis since, when taken in the recommended dosage, it can result in a small but significant decline in  $\text{SaO}_2$  in stable COPD.<sup>53</sup> It is unknown whether there are additive side effects when LABAs are used in combination with high doses of SABAs. Alternatively, some of the non-bronchodilator effects of LABAs<sup>51</sup>—such as inhibition of inflammatory mediator release, stimulation of mucociliary transport, and attenuation of neutrophil recruitment and activation—could be beneficial for some of the pathobiological aspects of exacerbations. The recent observation of significant lung hyperinflation in patients with acute COPD<sup>40–41</sup> may be important as LABDs reduce hyperinflation at rest<sup>54</sup> and during exercise.<sup>55–57</sup> There is also emerging evidence that a combination of a LABA and tiotropium bromide may have complementary effects.<sup>48–58</sup> Furthermore, there is some evidence that tiotropium bromide may have some anti-inflammatory effects.<sup>49–59–60</sup>

### Methylxanthines (theophylline)

Theophylline has been relegated to second line intravenous treatment for the management of exacerbations in patients with an inadequate or insufficient response to SABDs.<sup>61</sup> Compared with placebo, most studies with intravenous theophylline have shown marginal effects on symptoms, hospital admission rate, acid-base balance, and lung function

(FEV<sub>1</sub> and arterial blood gases) in non-acidotic patients.<sup>62–63</sup> When used in the clinical setting, physicians have to be aware of its many unwanted effects and interactions with other metabolic factors.

Despite its bronchodilating effects through directly relaxing human airways smooth muscle cells possibly by phosphodiesterase inhibition, there is increasing evidence of anti-inflammatory effects at low serum concentrations.<sup>49</sup> The recent finding that theophylline activates histone deacetylases—nuclear enzymes involved in the switching off of activated inflammatory genes—is of further pathogenic and therapeutic interest.<sup>64–66</sup>

### Systemic corticosteroids

The role of systemic corticosteroids in treating patients with exacerbations has remained contentious for almost 20 years. Since the original study in which significant improvements in pre and post bronchodilator FEV<sub>1</sub> values were seen in hospital inpatients with exacerbations treated with intravenous methylprednisolone (0.5 mg/kg four times daily for 3 days) compared with placebo,<sup>67</sup> five relevant RCTs in outpatients and inpatients with moderate to severe exacerbations of COPD<sup>68–72</sup> and three systematic reviews<sup>34–73–74</sup> have led conclusively to the evidence based systemic use of corticosteroids for exacerbations of COPD (table 1).

Two studies were carried out in outpatients. In the first,<sup>68</sup> patients presenting with non-acidotic exacerbations were randomised to a 9 day course of either oral prednisone in a tapering dose (starting with 60 mg once daily for 3 days) or placebo. Compared with the placebo group, there was a more rapid improvement in FEV<sub>1</sub> (by 18% and 37%) and in moderate hypoxaemia (by 23% and 26%) on days 3 and 10 compared with day 1 in the treatment group. The most important finding was that treatment failure was significantly more frequent in the placebo group. In the second study<sup>69</sup> 40 mg oral prednisone or placebo was given once daily for 10 days to a cohort of patients with severe exacerbations of COPD after discharge from an emergency department. Compared with placebo, the active treatment significantly reduced the overall relapse rate at 30 days (27% versus 43%), suggesting that for every six patients treated with steroids, one relapse in 30 days was avoided. Compared with placebo, post bronchodilator FEV<sub>1</sub> improved (34% (300 ml) v 15% (160 ml) from baseline) and breathlessness improved significantly after prednisone without differences in hospital admission rates or mortality. The steroid group was, however, more likely to have insomnia, increased appetite, and weight gain with trends toward a higher incidence of depression and anxiety.

In the largest inpatient study of COPD exacerbations to date,<sup>70</sup> patients received either 125 mg intravenous methylprednisolone four times daily for 3 days followed by 8 or 2 weeks of a tapering dose of oral prednisone (starting with 60 mg once daily), while the third group received placebo. Compared with placebo, the treatment failure rate was significantly less in the combined steroid group on days 30 (33% v 23%) and 90 (48% v 37%) but not at 6 months. The length of hospital stay was shortened by 1 day and FEV<sub>1</sub> improved more rapidly in the steroid group (by approximately 100 ml) from day 1 but did not differ by 2 weeks. Adverse events were, however, more noticeable in the steroid treated group (67% patients had diabetes), including hyperglycaemia requiring treatment (15%) and a higher proportion of secondary infection in the group treated for 8 weeks. The duration of steroid treatment did not influence these outcomes.

In another study<sup>71</sup> patients with severe COPD admitted to hospital for a non-acidotic exacerbation were assigned to oral prednisolone (30 mg once daily) or placebo for 2 weeks.



Changes in post bronchodilator FEV<sub>1</sub> were greater after steroids with increases of 90 ml daily up to day 5 of hospital stay and earlier plateaus compared with the placebo group. At discharge, pre bronchodilator and post bronchodilator FEV<sub>1</sub> values rose significantly in the corticosteroid group (from 27% to 38% and from 28% to 42%, respectively), with no differences at 6 weeks. The spirometric changes were matched by improvements in symptoms during admission in the two groups, the greatest changes being seen in sleep quality, shortness of breath, mobility, and general well-being. The median length of hospital stay was reduced by 2 days in the corticosteroid group. There was no difference in exacerbation or re-admission rates or in the treatment received between the two intervention groups. Transient glycosuria was the major adverse event observed in the active treatment group.

The third RCT in inpatients<sup>72</sup> compared nebulised budesonide 0.5 mg/ml (2 mg four times daily for 3 days followed by 2 mg per day for 7 days) with oral prednisolone (30 mg twice daily for 3 days followed by 40 mg once daily for 7 days) and with placebo in patients with severe COPD hospitalised for moderate to severe non-acidotic exacerbations. Compared with the placebo group, post bronchodilator changes in FEV<sub>1</sub> within the first 3 days of treatment were more rapid in both active treated groups (budesonide by 100 ml, prednisolone by 160 ml, no difference between them) but these had abated at 2 weeks. Pre bronchodilator FEV<sub>1</sub> was higher in both active treatment groups than in the placebo group, but only significantly so (by 120 ml) in those who received prednisolone. Dyspnoea fell substantially in all the three groups, and there were small but significant increases in Pao<sub>2</sub> in the prednisolone group together with a small decrease in arterial carbon dioxide tension (Paco<sub>2</sub>) which was significant in both active groups. Length of hospital stay and corticosteroid related adverse events were similar in the three groups, with disease deterioration as the most serious event in those receiving prednisolone. Hyperglycaemia was more common in the steroid group than in the other three subsets.

In another inpatient study<sup>75</sup> no differences were seen between intravenous and oral steroid treatment and between aerosol and MDI SABB treatment of exacerbations and, in another study,<sup>76</sup> patients with frequent severe exacerbations needing hospital admission showed greater improvements in pre bronchodilator FEV<sub>1</sub> and Pao<sub>2</sub> and in dyspnoea on exertion after a 10 day course of intravenous methylprednisolone than after a 3 day course.

The mechanisms for improving lung function and other outcomes and the patients most likely to benefit from steroid treatment during exacerbations remain contentious. No clinical, biochemical, or functional markers can clearly identify which patients will respond better to steroid treatment. Although no effects on airway cytokines have been found in patients with stable COPD,<sup>77</sup> two studies have reported reductions in airway eosinophilic inflammatory markers<sup>78</sup> and in serum C-reactive protein (CRP) after 2 weeks of treatment with oral steroids.<sup>27</sup> The beneficial response to steroids during exacerbations suggests that enhanced airway inflammation and oedema<sup>25–27</sup> and systemic inflammation<sup>25–28</sup> are reduced, or that the inflammatory pattern is sensitive to corticosteroids.<sup>49</sup> An increased number of eosinophils has been found in patients with mild to moderate COPD exacerbations.<sup>79</sup> Treatment with oral steroids for 10–14 days in an outpatient setting reduced some markers of sputum neutrophilic inflammation such as the chemoattractants interleukin-8 and tumour necrosis factor- $\alpha$  during the recovery phase, and these increased at the nadir of the exacerbation.<sup>25–80</sup> In inpatients with exacerbations, steroid use for 7 days significantly reduced serum CRP and lipopolysaccharide binding protein levels, markers of systemic inflammation.<sup>28–81</sup>

These RCTs all have some limitations in common. Only a minority of many screened patients were eventually enrolled in the studies as patients taking systemic steroids regularly during the preceding month were excluded. This suggests that regular systemic steroid therapy is common, particularly among those with the most severe and unstable clinical profile who, in turn, may exhibit more frequent acute episodes. In addition, very few patients were receiving regular LABDs and/or fixed combination inhalers, hence ignoring the complementary effects of these agents as an adjunct therapy in exacerbations. A subgroup analysis suggested that the benefits of steroid treatment were associated with a more favourable outcome in patients with previous exacerbations who needed admission to hospital.<sup>70</sup> It is possible that the response of these patients may be greater following repeat treatment with steroids than in those who had not previously received systemic treatment. Adverse events are not sufficiently known, particularly in the medium and long term—a serious drawback given the high prevalence of co-morbidities in most of these elderly patients. Although the optimum duration and dosage of steroid treatment has not been established, a starting dose of 30–40 mg/day and treatment duration of 7 days have been consistently recommended.

### Antibiotics

The use of antibiotics in exacerbations of COPD remains unsettled despite their extensive use. It is unlikely that the majority of patients will benefit from a short course of antibiotics during exacerbations (table 1). The most frequent aetiology of an exacerbation is infection of the lower airways and/or air pollution, even though the cause of one third of exacerbations is still ignored.<sup>82</sup> Patients with COPD have bacteria in high concentrations in their lower airways during both exacerbations and stable conditions (airway colonisation).<sup>83–84</sup> This concept of the causative role of bacterial microorganisms has been reinforced by the isolation of new strains of a bacterial pathogen with development of specific immune responses.<sup>85–86</sup> The predominant bacterial microorganisms recovered from the airways of patients with mild exacerbations are *Haemophilus influenzae*, *Streptococcus pneumoniae* and *Moraxella catarrhalis*<sup>83</sup> while, in patients with severe COPD episodes, enteric Gram negative bacilli and *Pseudomonas aeruginosa* may be more important.<sup>84</sup> Viral infections (picornaviruses, influenza A and respiratory syncytial virus) are likely to play a part in severe exacerbations.<sup>87–88</sup>

A seminal study by Anthonisen *et al*<sup>89</sup> provided strong evidence that antibiotics have a significant effect on PEFR and lead to an earlier resolution of all three of the cardinal symptoms defining exacerbations (increased dyspnoea, increased sputum volume, and increased sputum purulence). Stockley *et al*<sup>90</sup> showed a relationship between sputum purulence and the presence of bacteria, suggesting that these patients should be treated with antibiotics if they also have at least one of the other two symptoms (dyspnoea or increased sputum volume). Of the three systematic reviews of the use of antibiotic treatment in the presence of purulent sputum,<sup>91–92</sup> the most recent<sup>92</sup> observed a reduction in the risk of mortality, treatment failure, and sputum purulence. However, these results need to be viewed with some caution, given the difference in patient selection, antibiotic choice, small number of trials, and lack of control for other therapeutic interventions that influence outcome. Compared with placebo, patients with exacerbations mechanically ventilated and treated with an oral antibiotic (ofloxacin) had reduced mortality, needed fewer additional antibiotics, and had a shorter duration of ventilator treatment and length of hospital stay.<sup>93</sup>

**Table 2** Antibiotic treatment in exacerbations (taken from GOLD<sup>10</sup>)

	Oral treatment (no particular order)	Alternative (no particular order)	Parenteral treatment (no particular order)
Group A: Patients not needing hospitalisation (mild COPD)	Patients with only one cardinal symptom should not receive antibiotics If indication then: β-lactam (ampicillin/amoxicillin) Tetracycline Trimethoprim/sulfamethoxazole	β-lactam/β-lactamase inhibitor (Co-amoxiclav) Macrolides: azithromycin, clarithromycin, roxithromycin Cephalosporins (2nd or 3rd generation) Ketolides (telithromycin)	
Group B: Patients admitted to hospital (moderate to very severe COPD without risk of <i>P aeruginosa</i> )	β-lactam/β-lactamase inhibitor (Co-amoxiclav)	Fluoroquinolones: gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin	β-lactam/β-lactamase inhibitor (Co-amoxiclav, ampicillin/sulbactam) Cephalosporins (2nd or 3rd generation) Fluoroquinolones: gatifloxacin, levofloxacin, moxifloxacin
Group C: Patients admitted to hospital (moderate to very severe COPD with risk of <i>P aeruginosa</i> )	Fluoroquinolones: ciprofloxacin, levofloxacin (high dose)		Fluoroquinolones: ciprofloxacin, levofloxacin (high dose) or β-lactam with <i>P aeruginosa</i> activity

According to GOLD recommendations,<sup>10</sup> antibiotics should be given to patients with exacerbations with the three major symptoms,<sup>89</sup> to those with two symptoms provided increased sputum purulence is present, and to those who are critically ill and needing mechanical support. The oral route is preferred and is cheaper.<sup>10</sup> Their administration should be based on the patterns of local bacterial resistance<sup>9</sup> and their use should be maintained for a period of 3–10 days (table 2).<sup>10</sup> If an exacerbation responds poorly to empirical antibiotic treatment, the patient should be re-evaluated for complications with microbiological reassessment if necessary.

### Respiratory stimulants

In the 1970s and 1980s both doxapram<sup>94</sup> and almitrine bismesylate<sup>10–95</sup> were in their heydays and were the two most recommended drugs for treating chronic and acute hypercapnic respiratory failure in patients with COPD. However, almitrine, a relatively specific peripheral chemoreceptor, was associated with serious adverse effects (peripheral neuropathy and weight loss) in stable COPD without significant effects on mortality or quality of life. Serious flaws in the design of the RCTs together with the robustness of evidence based effects of non-invasive ventilation (NIV) in patients with acute COPD have relegated the use of doxapram to those very unusual clinical situations in which NIV is not available or not indicated.<sup>12</sup>

### Adjunct therapies

An appropriate fluid balance with special attention to the administration of diuretics,<sup>13</sup> nutritional aspects, anticoagulants, and cardiovascular agents are the most complementary standard measures.<sup>10</sup> At any time, physicians will strongly enforce stringent measures against active cigarette smoking.

### NON-PHARMACOLOGICAL TREATMENT

Two major non-pharmacological approaches—namely, oxygen therapy and ventilatory support—are widely used in the most severe exacerbations of COPD.<sup>96–99</sup> These approaches are now complemented by the use of structured management programmes described as “hospital at home” (HaH)<sup>100–101</sup> and pulmonary rehabilitation introduced in the recovery period after hospitalisation.<sup>102</sup>

A clinical condition characterised by decreased PaO<sub>2</sub> with or without increased PaCO<sub>2</sub> can be a practical definition for

acute (or acute-on-chronic) respiratory failure during an exacerbation of COPD. It occurs when the respiratory system cannot cope with adequate alveolar ventilation to pulmonary blood flow balance in the presence of severely abnormal lung mechanics. Both arterial hypoxaemia and hypercapnia are dominated in part by further ventilation-perfusion imbalance.<sup>3–29</sup> Hypercapnia is, however, also greatly influenced by lung mechanical abnormalities due to the limitations of the respiratory pump in maintaining effective alveolar ventilation.<sup>29</sup> Both increased airways obstruction and lung hyperinflation<sup>40–41–103</sup> superimpose an excessive elastic and resistive load on the respiratory pump so that the respiratory muscles are overburdened and operate at a mechanical disadvantage.<sup>103–104</sup> Moreover, there is an inspiratory threshold load due to increased inspiratory positive end expiratory pressure.<sup>29b–105</sup> With this overload of the respiratory muscle pump, alveolar ventilation cannot be sustained effectively and hypercapnia, acidosis, and further hypoxaemia ensue. The capacity of the respiratory pump is further compromised by the detrimental effects of acidosis on the respiratory muscles<sup>106</sup> which, in turn, results in superimposed muscle fatigue<sup>107</sup> creating a vicious cycle that further aggravates the acid-base status and gas exchange. This is why arterial pH and blood gases are central physiological outcomes for assessing acute respiratory failure during exacerbations of COPD.

### Controlled oxygen therapy

Oxygen therapy is of great beneficial value in acute respiratory failure during exacerbations. Its primary objective is to raise PaO<sub>2</sub> to prevent life threatening hypoxaemia in order to optimise oxygen delivery to peripheral tissues and alleviate symptoms, mostly dyspnoea (table 3). In clinical practice, physicians administer controlled low inspired oxygen concentrations (either 24% or 28%) through high flow (Venturi) masks at flow rates of 2–4 l/min. This strategy increases PaO<sub>2</sub> sufficiently (1.3–2.0 kPa or 10–15 mg) to maintain optimal values above 8.0 kPa (60 mm Hg) and to ensure adequate SaO<sub>2</sub> levels (≥90%) without risking detrimental carbon dioxide retention and acidosis. Low flow devices such as nasal prongs or cannulae are less accurate as they deliver a variable and higher inspired oxygen concentration which can result in suppression of respiratory drive, carbon dioxide narcosis, and eventually respiratory arrest<sup>108</sup> if

the patient is not appropriately monitored. Although these concepts are clearly established, well designed trials in this field are lacking.<sup>109</sup> Ideally, arterial blood gas analysis from radial stabs (or from another peripheral artery) provides the most accurate assessment. Ear lobe gases are of more limited use as they accurately reflect  $\text{PaCO}_2$  only.<sup>110–111</sup> Pulse oximetry is a non-invasive alternative which is useful for trending and/or adjusting oxygen therapy settings. The optimal strategy for oxygen therapy during exacerbations is shown in fig S1 available online only at <http://www.thoraxjnl.com/supplemental>. During moderate to severe exacerbations, arterial pH and blood gas tensions should always be measured before and 1 hour after starting oxygen therapy.

When 100% oxygen is breathed in clinical practice during invasive ventilation only, there is a further ventilation-perfusion mismatch which indicates the release of hypoxic pulmonary vasoconstriction without development of reabsorption atelectasis (that is, increased intrapulmonary shunt).<sup>112</sup> The administration of 100% oxygen, either by spontaneous breathing or via ventilatory support, results in further hypercapnia mainly attributed to increased dead space.<sup>112–114</sup>

### Assisted mechanical support

The primary therapeutic goal of ventilatory support in patients with exacerbations with acute respiratory failure is to decrease both mortality and morbidity and to relieve symptoms, despite optimal medical treatment.<sup>9–12</sup> Mechanical ventilation can be delivered non-invasively or invasively (conventionally) using different modes that are, in essence, positive pressure devices (negative ventilation is currently not recommended) for non-invasive ventilation using either a nasal or facial mask, or via an endotracheal tube or a tracheostomy for invasive ventilation.

When assessing the suitability of patients with advanced COPD for mechanical ventilation, many factors must be taken into account including the patient's age, disease severity, co-morbidities, prior functional status, and experience during previous exacerbations, especially where ventilatory support has been required. Patients with end stage COPD with at least one hospital admission for hypercapnic respiratory failure have a worse health status and emotional well being than patients with unresectable non-small cell

lung cancer and receive less holistic care appropriate to their needs.<sup>115</sup> These findings are even more important if we consider that the quality of the patient-physician communication regarding end of life care from the patient's perspective—such as talking about the prognosis, dying and spirituality—is rated poorly by oxygen dependent patients with advanced COPD.<sup>116</sup> Patients with severe exacerbations requiring ventilatory support may find the treatment more burdensome than the benefit in terms of prolonged life that it offers, and there are no predictive features to identify this. In principle, autonomy of the patient should be the key ethical principle to guide physicians, patients, and relatives in choosing the most suitable end of life decision making process.<sup>9–10</sup>

### Non-invasive ventilation (NIV)

This treatment is now widely used in acidotic hypercapnic exacerbations of COPD. The criteria to identify patients who will benefit are straightforward and are shown in table 3 (see also table S2 and fig S1 available online only at <http://www.thoraxjnl.com/supplemental>). It can be delivered using air, with or without mixed oxygen. The improvement in gas exchange and acid-base effects by NIV reflects improved alveolar ventilation which results from a change in breathing pattern to a slower, deeper, more physiological pattern with no change in the underlying ventilation-perfusion imbalance.<sup>117–118</sup> A systematic review<sup>119</sup> based on several RCTs<sup>120–126</sup> provided evidence that NIV—as an adjunct to standard medical care—decreased mortality, the need for endotracheal intubation (for every five patients treated with NIV one patient would avoid intubation), and treatment failure. Moreover, NIV increased pH, reduced hypercapnia and the respiratory rate within 1 hour of its institution, shortened the length of hospital stay by more than 3 days irrespective of environment (high dependency/intensive care unit versus medical ward), and decreased complications associated with treatment. NIV is cost effective compared with usual therapeutic care alone.<sup>127–128</sup> The current recommendation is to deliver NIV in a controlled environment with a dedicated setting led by experienced and well trained personnel.<sup>9–10–12</sup>

### Invasive ventilation

The most life threatening episodes of acute respiratory failure exacerbations can benefit from the use of invasive ventilation (see table 3 and table S2 and fig S1 available in the online supplement at <http://www.thoraxjnl.com/supplemental>). Despite the need for invasive ventilation, relatively good survival is achieved with mortality rates of 11–49%.<sup>1–97–99</sup> These figures are, however, considerably lower than those observed in patients with respiratory failure from other aetiologies treated in general intensive care settings.<sup>129</sup> Compared with acute respiratory distress syndrome (ARDS), the mean duration of ventilation in acute COPD was significantly shorter (9 v 5 days)<sup>129</sup> or even lower (median 2 days), as was the length of stay in the intensive care unit (1 v 25 days).<sup>99</sup>

NIV has been used to shorten the period of invasive ventilation in cases of weaning failure and in those with a long stay in the intensive care unit.<sup>130–131</sup> However, a large scale RCT in unselected patients needing mechanical ventilation found that NIV was not effective in avoiding the need for re-intubation and did not reduce mortality.<sup>132</sup>

### Pulmonary rehabilitation (physiotherapy)

Pulmonary rehabilitation is a multidisciplinary programme particularly suited for all patients with COPD except those with stable stage I disease.<sup>9–10–13–133</sup> However, other than manual chest percussion<sup>10</sup> and physiotherapy using positive expiratory pressure masks for selected patients<sup>12</sup> to help in clearing sputum, pulmonary rehabilitation has no indication

**Table 3** What is known of non-pharmacological treatment

#### Controlled oxygen support

- Improves  $\text{PaO}_2$  with small  $\text{PaCO}_2$  increases
- Abates dyspnoea
- Use high flow (Venturi) devices
- Repeat arterial blood gas measurements in moderate to severe exacerbations
- Use pulse oximetry (for  $\text{SaO}_2$  assessment) for mild exacerbations

#### Mechanical ventilation

##### Non-invasive ventilation:

- Reduces respiratory rate and improves  $\text{PaO}_2$ ,  $\text{PaCO}_2$ , and pH
- Decreases mortality, need for intubation, treatment failure, and length of hospital stay
- Cost effective intervention
- Deliver in a controlled setting

##### Invasive ventilation:


- Improves life threatening acute respiratory failure
- Good survival
- Suitability of intubation and ventilation

#### Pulmonary rehabilitation

- No indication

$\text{PaO}_2$ ,  $\text{PaCO}_2$ , arterial oxygen and carbon dioxide tension.






**Figure 2** Management scheme for patients with mild to moderate exacerbations of COPD. Reproduced from Rodriguez-Roisin *et al*<sup>30</sup> with permission from Prous Science.

in exacerbations of COPD. It can, however, have an adjunct therapeutic role in exacerbations. One study showed that a comprehensive home care intervention, which included a simple pulmonary rehabilitation programme together with standardised pharmacological treatment delivered by specialised nurses in selected non-acidotic patients with exacerbations admitted to emergency departments, could be used to treat exacerbations at home safely.<sup>100</sup> An 8 week course of pulmonary rehabilitation using a multifaceted programme instituted shortly after admission to hospital for an exacerbation resulted in substantial improvements in exercise capacity and health related quality of life at 3 months.<sup>102</sup>

**HOSPITAL AT HOME (HAH) AND SUPPORTED DISCHARGE SERVICES**

HaH services represent a new healthcare model which are potentially appealing for the management of selected non-acidotic patients with exacerbations of COPD presenting to emergency departments.<sup>100</sup> At first glance, patients with altered mental status or confusion, acute ECG or radiographic



**Figure 3** Management scheme for patients with moderate to severe exacerbations of COPD. ABG, arterial blood gases. Reproduced from Rodriguez-Roisin *et al*<sup>30</sup> with permission from Prous Science.

changes, serious co-morbidities, and/or poor social conditions should not be eligible for these healthcare schemes. There are three objectives for these patients to be safely cared for at home: (1) immediate or early discharge from the hospital to avoid or shorten length of hospital stay; (2) provision of a tailored individualised management programme; and (3) home support by a skilled specialised respiratory team. The major finding of the most recent meta-analysis<sup>101</sup> including several robust RCTs<sup>134-140</sup> concluded that HaH services could be used as safely as hospital care. Compared with inpatient care, patients assigned to HaH generated substantial financial savings, mostly due to a shorter hospital stay.

**CONCLUSIONS**

Exacerbations can be managed at home or in hospital, depending on factors and aspects considered in the diagnostic assessment (see table S3 available online only at <http://www.thoraxjnl.com.supplemental>). Nevertheless, with the exception of ventilatory support, most of the therapeutic approaches discussed are available at home and can be used safely. Accordingly, HaH and supported discharge programmes are likely to become more common and extensively applied in the future. Management schemes for patients with mild to moderate exacerbations and for those with moderate to severe exacerbations<sup>30</sup> are shown in figs 2 and 3, respectively, and are dealt with in greater detail by GOLD<sup>10</sup> and the ATS/ERS guidelines;<sup>9</sup> both are based essentially on the clinical presentation of the patient. However, grading of the severity of mild to moderate exacerbations remains contentious<sup>19</sup> since they can be categorised either on clinical presentation (essentially symptoms)<sup>89</sup> or healthcare use resources.<sup>18</sup> Detailed discharge from hospital and general follow up measures will be actively reinforced after exacerbations.<sup>9 10</sup>

**ACKNOWLEDGEMENTS**

The author thanks Laura Morte for her secretarial support. Figures 1, 2 and 3 are reproduced from Rodriguez-Roisin *et al*<sup>30</sup> with permission from Prous Science.



Tables S1-S3 and fig S1 are available online only at <http://www.thoraxjnl.com/supplemental>.

Supported by the Red Respira-ISCIII-RTIC-03/11 and the Comissionat per a Universitats i Recerca de la Generalitat de Catalunya (2005 SGR-00822). Dr R R-R holds a career scientist award (2001-07) from the Generalitat de Catalunya.

Competing interests: The author has participated as a lecturer and speaker in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Laboratorios Dr Esteve SA and Pfizer; consulted with several pharmaceutical companies with relevance to the topics discussed in the present article (Almirall, Altana, AstraZeneca, Aventis, Boehringer Ingelheim, GlaxoSmithKline, Laboratorios Dr Esteve SA, Novartis, Pfizer, Viechi and Zambon); serves on advisory boards for Almirall, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Procter & Gamble and Viechi; has been sponsored for several clinical trials; and has received laboratory research support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Laboratorios Dr Esteve SA, Pfizer and Procter & Gamble Ltd.

**REFERENCES**

- 1 Gunen H, Hacievliyagil SS, Kosar F, *et al*. Factors affecting survival of hospitalised patients with COPD. *Eur Respir J* 2005;**26**:234-41.
- 2 Soler-Cataluna JJ, Martinez-Garcia MA, Roman SP, *et al*. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. *Thorax* 2005;**60**:925-31.
- 3 Barbera JA, Roca J, Ferrer A, *et al*. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. *Eur Respir J* 1997;**10**:1285-91.

- 4 Kessler R, Faller M, Fourgaut G, et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999;159:158–64.
- 5 Roberts CM, Ryland I, Lowe D, et al. Audit of acute admissions of COPD: standards of care and management in the hospital setting. *Eur Respir J* 2001;17:343–9.
- 6 Garcia-Aymerich J, Barreiro E, Ferrero E, et al. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). *Eur Respir J* 2000;16:1037–42.
- 7 Kidney J, McManus T, Coyle PV. Exacerbations of chronic obstructive pulmonary disease. *Thorax* 2002;57:753–4.
- 8 European Respiratory Society. *European Lung White Book*, 1st ed. European Respiratory Society Journals, 2003.
- 9 Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J* 2004;23:932–46.
- 10 Global Initiative for Chronic Obstructive Pulmonary Disease. *Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, Executive Summary*. 2005. Available at [www.goldcopd.com](http://www.goldcopd.com).
- 11 Barbera JA, Peces-Barba G, Agusti AG, et al. [Clinical guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease]. *Arch Bronconeumol* 2001;37:297–316.
- 12 National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease: national clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. *Thorax* 2004;59(Suppl 1):1–232.
- 13 Wouters EF. Management of severe COPD. *Lancet* 2004;364:883–95.
- 14 Rennard SI. Treatment of stable chronic obstructive pulmonary disease. *Lancet* 2004;364:791–802.
- 15 Fabbri LM, Hurd SS. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. *Eur Respir J* 2003;22:1–2.
- 16 Wilkinson TM, Donaldson GC, Hurst JR, et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2004;169:1298–303.
- 17 Vestbo J. What is an exacerbation of COPD? *Eur Respir Rev* 2004;13:6–13.
- 18 Rodríguez-Roisin R. Toward a consensus definition for COPD exacerbations. *Chest* 2000;117:398–401S.
- 19 Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. *Eur Respir J Suppl* 2003;41:46–53S.
- 20 Holleman DR Jr, Simel DL. Does the clinical examination predict airflow limitation? *JAMA* 1995;273:313–9.
- 21 Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. *Eur Respir J* 1995;8:1398–420.
- 22 Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. *Ann Intern Med* 2001;134:600–20.
- 23 Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998;157:1418–22.
- 24 Emerman CL, Cydulka RK. Use of peak expiratory flow rate in emergency department evaluation of acute exacerbation of chronic obstructive pulmonary disease. *Ann Emerg Med* 1996;27:159–63.
- 25 Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001;163:349–55.
- 26 Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. *Thorax* 2000;55:114–20.
- 27 Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2004;170:760–5.
- 28 Dentener MA, Creutzberg EC, Schols AM, et al. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. *Thorax* 2001;56:721–6.
- 29a Rodríguez-Roisin R, MacNee W. Pathophysiology of chronic obstructive pulmonary disease. *Eur Respir Mon* 1998;7:107–26.
- 29b O'Aonell DE, Parker CM. COPD exacerbations-3: Pathophysiology. *Thorax* 2006;61:354–61.
- 30 Rodríguez-Roisin R, Lloyd-Owen S, Wedzicha JA, et al. Exacerbations of COPD. *Timely Topics in Medicine*, Prous Science, 2003. Available at [www.timed.com/respiratory](http://www.timed.com/respiratory).
- 31 Johnson M, Rennard S. Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. *Chest* 2001;120:258–70.
- 32 Costello R. Pharmacology. In: Calverley PM, MacNee W, Pride N, Rennard SI, eds. *Chronic obstructive pulmonary disease*. 2nd ed. London: Arnold, 2003:341–56.
- 33 McCrory DC, Brown CD. Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2002;CD003900.
- 34 McCrory DC, Brown C, Gelfand SE, et al. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. *Chest* 2001;119:190–209.
- 35 Karpel JP, Pesin J, Greenberg D, et al. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. *Chest* 1990;98:835–9.
- 36 Rebeck AS, Chapman KR, Abboud R, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. *Am J Med* 1987;82:59–64.
- 37 Johnson MK, Stevenson RD. Management of an acute exacerbation of COPD: are we ignoring the evidence? *Thorax* 2002;57(Suppl II):i15–23.
- 38 Centanni S, Santus P, Casanova F, et al. Bronchodilating effect of oxitropium bromide in heart disease patients with exacerbations of COPD: double-blind, randomized, controlled study. *Respir Med* 2002;96:137–41.
- 39 Polverino E, Gomez FP, Rodrigues AS, et al. Nebulized salbutamol transiently deteriorates pulmonary gas exchange in COPD exacerbations (abstract). *Proc Am Thorac Soc* 2005;2:A406.
- 40 Parker CM, Voduc N, Aaron SD, et al. Physiologic changes during symptom recovery from moderate exacerbation of COPD. *Eur Respir J* 2005;26:420–8.
- 41 Stevenson NJ, Walker PP, Costello RW, et al. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005;172:1510–6.
- 42 COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. *Chest* 1997;112:1514–21.
- 43 Patrick DM, Dales RE, Stark RM, et al. Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium to usual therapy. *Chest* 1990;98:295–7.
- 44 Moayyedi P, Congleton J, Page RL, et al. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. *Thorax* 1995;50:834–7.
- 45 Turner MO, Patel A, Ginsburg S, et al. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. *Arch Intern Med* 1997;157:1736–44.
- 46 Tattersfield AE, Lofdahl CG, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. *Lancet* 2001;357:257–61.
- 47 Malolepszy J, Boszormenyi NG, Selroos O, et al. Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction. *Eur Respir J* 2001;18:928–34.
- 48 Cazzola M, Di Marco F, Santus P, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. *Pulm Pharmacol Ther* 2004;17:35–9.
- 49 Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. *Eur Respir J* 2005;25:1084–106.
- 50 Ferguson GT, Funck-Brentano C, Fischer T, et al. Cardiovascular safety of salmeterol in COPD. *Chest* 2003;123:1817–24.
- 51 Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. *Chest* 2004;125:2309–21.
- 52 Suissa S, Assimes T, Ernst P. Inhaled short acting beta agonist use in COPD and the risk of acute myocardial infarction. *Thorax* 2003;58:43–6.
- 53 Khoukaz G, Gross NJ. Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease. Comparison with albuterol and ipratropium. *Am J Respir Crit Care Med* 1999;160:1028–30.
- 54 Celli B, ZuWallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. *Chest* 2003;124:1743–8.
- 55 O'Donnell DE, Voduc N, Fitzpatrick M, et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. *Eur Respir J* 2004;24:86–94.
- 56 O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. *Eur Respir J* 2004;23:832–40.
- 57 Rodríguez-Roisin R. Is this the beginning of unravelling the puzzle of COPD exacerbations? *Eur Respir J* 2005;26:376–8.
- 58 van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. *Eur Respir J* 2005;26:214–22.
- 59 Kawashima K, Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity. *Life Sci* 2003;74:675–96.
- 60 Wessler I, Kilbinger H, Bittinger F, et al. The non-neuronal cholinergic system in humans: expression, function and pathophysiology. *Life Sci* 2003;72:2055–61.
- 61 Barr RG, Rowe BH, Camargo CA Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. *BMJ* 2003;327:643.
- 62 Barbera JA, Reyes A, Roca J, et al. Effect of intravenously administered aminophylline on ventilation/perfusion inequality during recovery from exacerbations of chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1992;145:1328–33.
- 63 Duffy N, Walker P, Diamantea F, et al. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. *Thorax* 2005;60:713–7.
- 64 Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. *Proc Natl Acad Sci USA* 2002;99:8921–6.
- 65 Cosio BG, Tsaprouni L, Ito K, et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. *J Exp Med* 2004;200:689–95.
- 66 Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. *N Engl J Med* 2005;352:1967–76.
- 67 Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. *Ann Intern Med* 1980;92:753–8.
- 68 Thompson WH, Nielson CP, Carvalho P, et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. *Am J Respir Crit Care Med* 1996;154:407–12.



- 69 **Aaron SD**, Vandemheen KL, Hebert P, *et al*. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. *N Engl J Med* 2003;**348**:2618–25.
- 70 **Niewoehner DE**, Erbland ML, Deupree RH, *et al*. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. *N Engl J Med* 1999;**340**:1941–7.
- 71 **Davies L**, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. *Lancet* 1999;**354**:456–60.
- 72 **Mallat F**, Ostinelli J, Bourbeau J, *et al*. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. *Am J Respir Crit Care Med* 2002;**165**:698–703.
- 73 **Singh JM**, Palda VA, Stanbrook MB, *et al*. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. *Arch Intern Med* 2002;**162**:2527–36.
- 74 **Wood-Baker RR**, Gibson PG, Hannay M, *et al*. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2005;CD001288.
- 75 **Willaert W**, Doenen M, Bomans P, *et al*. What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? *Eur Respir J* 2002;**19**:928–35.
- 76 **Sayiner A**, Aylemurt ZA, Cirit M, *et al*. Systemic glucocorticoids in severe exacerbations of COPD. *Chest* 2001;**119**:726–30.
- 77 **Keatings VM**, Jatakanon A, Worsdell YM, *et al*. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. *Am J Respir Crit Care Med* 1997;**155**:542–8.
- 78 **Brightling CE**, Monteiro W, Ward R, *et al*. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet* 2000;**356**:1480–5.
- 79 **Saetta M**, Di Stefano A, Maestrelli P, *et al*. Airway eosinophilia in chronic bronchitis during exacerbations. *Am J Respir Crit Care Med* 1994;**150**:1646–52.
- 80 **Drost EM**, Skwarski KM, Sauleda J, *et al*. Oxidative stress and airway inflammation in severe exacerbations of COPD. *Thorax* 2005;**60**:293–300.
- 81 **Agusti AG**, Noguera A, Sauleda J, *et al*. Systemic effects of chronic obstructive pulmonary disease. *Eur Respir J* 2003;**21**:347–60.
- 82 **White AJ**, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease. 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. *Thorax* 2003;**58**:73–80.
- 83 **Monso E**, Ruiz J, Rosell A, *et al*. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. *Am J Respir Crit Care Med* 1995;**152**:1316–20.
- 84 **Soler N**, Torres A, Ewig S, *et al*. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. *Am J Respir Crit Care Med* 1997;**157**:1498–505.
- 85 **Sethi S**, Wrona C, Grant BJ, *et al*. Strain-specific immune response to *Haemophilus influenzae* in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2004;**169**:448–53.
- 86 **Sethi S**, Evans N, Grant BJ, *et al*. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 2002;**347**:465–71.
- 87 **Rohde G**, Wiethege A, Borg I, *et al*. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. *Thorax* 2003;**58**:37–42.
- 88 **Fagon JY**, Chastre J, Trouillet JL, *et al*. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. *Am Rev Respir Dis* 1990;**142**:1004–8.
- 89 **Anthonisen NR**, Manfreda J, Warren CP, *et al*. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987;**106**:196–204.
- 90 **Stockley RA**, O'Brien C, Pye A, *et al*. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. *Chest* 2000;**117**:1638–45.
- 91 **Saint S**, Bent S, Vittinghoff E, *et al*. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. *JAMA* 1995;**273**:957–60.
- 92 **Ram FS**, Rodriguez-Roisin R, Granados-Navarrete A, *et al*. Antibiotics for exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2006;**2**:CD004403.
- 93 **Nouira S**, Marghli S, Belghith M, *et al*. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. *Lancet* 2001;**358**:2020–5.
- 94 **Greenstone M**, Lasserson TJ. Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*, 2003, CD000223.
- 95 **Bardsley PA**, Howard P, DeBacker W, *et al*. Two years treatment with almitrine bismesylate in patients with hypoxic chronic obstructive airways disease. *Eur Respir J* 1991;**4**:308–10.
- 96 **Jeffrey AA**, Warren PM, Flenley DC. Acute hypercapnic respiratory failure in patients with chronic obstructive lung disease: risk factors and use of guidelines for management. *Thorax* 1992;**47**:34–40.
- 97 **Connors AF Jr**, Dawson NV, Thomas C, *et al*. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). *Am J Respir Crit Care Med* 1996;**154**:959–67.
- 98 **Senoff MG**, Wagner DP, Wagner RP, *et al*. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. *JAMA* 1995;**274**:1852–7.
- 99 **Breen D**, Churches T, Hawker F, *et al*. Acute respiratory failure secondary to chronic obstructive pulmonary disease treated in the intensive care unit: a long term follow up study. *Thorax* 2002;**57**:29–33.
- 100 **Gravil JH**, Al Rawas OA, Cotton MM, *et al*. Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service. *Lancet* 1998;**351**:1853–5.
- 101 **Ram FS**, Wedzicha JA, Wright J, *et al*. Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. *BMJ* 2004;**329**:315.
- 102 **Man WD**, Polkey MI, Donaldson N, *et al*. Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. *BMJ* 2004;**329**:1209.
- 103 **Macklem PT**. Hyperinflation. *Am Rev Respir Dis* 1984;**129**:1–2.
- 104 **Tobin MJ**, Perez W, Guenther SM, *et al*. The pattern of breathing during successful and unsuccessful trials of weaning from mechanical ventilation. *Am Rev Respir Dis* 1986;**134**:1111–8.
- 105 **Rossi A**, Gottfried SB, Zocchi L, *et al*. Measurement of static compliance of the total respiratory system in patients with acute respiratory failure during mechanical ventilation. The effect of intrinsic positive end-expiratory pressure. *Am Rev Respir Dis* 1985;**131**:672–7.
- 106 **Juan G**, Calverley P, Talamo C, *et al*. Effect of carbon dioxide on diaphragmatic function in human beings. *N Engl J Med* 1984;**310**:874–9.
- 107 **Roussos C**, Macklem PT. The respiratory muscles. *N Engl J Med* 1982;**307**:786–97.
- 108 **Agusti AG**, Carrera M, Barbe F, *et al*. Oxygen therapy during exacerbations of chronic obstructive pulmonary disease. *Eur Respir J* 1999;**14**:934–9.
- 109 **Bone RC**, Pierce AK, Johnson RL Jr. Controlled oxygen administration in acute respiratory failure in chronic obstructive pulmonary disease: a reappraisal. *Am J Med* 1978;**65**:896–902.
- 110 **Pitkin AD**, Roberts CM, Wedzicha JA. Arterialised earlobe blood gas analysis: an underused technique. *Thorax* 1994;**49**:364–6.
- 111 **Dall'Ava-Santucci J**, Dessanges JF, Dinh XAT, *et al*. Is arterialised earlobe blood PO<sub>2</sub> an acceptable substitute for arterial blood PO<sub>2</sub>? *Eur Respir J* 1996;**9**:1329–30.
- 112 **Santos C**, Ferrer M, Roca J, *et al*. Pulmonary gas exchange response to oxygen breathing in acute lung injury. *Am J Respir Crit Care Med* 2000;**161**:26–31.
- 113 **Aubier M**, Murciano D, Milic-Emili J, *et al*. Effects of the administration of O<sub>2</sub> on ventilation and blood gases in patients with chronic obstructive pulmonary disease during acute respiratory failure. *Am Rev Respir Dis* 1980;**122**:747–54.
- 114 **Robinson TD**, Freiberg DB, Regnis JA, *et al*. The role of hypoventilation and ventilation-perfusion redistribution in oxygen-induced hypercapnia during acute exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000;**161**:1524–9.
- 115 **Gore JM**, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. *Thorax* 2000;**55**:1000–6.
- 116 **Curtis JR**, Engelberg RA, Nielsen EL, *et al*. Patient-physician communication about end-of-life care for patients with severe COPD. *Eur Respir J* 2004;**24**:200–5.
- 117 **Brochard L**, Isabey D, Piquet J, *et al*. Reversal of acute exacerbations of chronic obstructive lung disease by inspiratory assistance with a face mask. *N Engl J Med* 1990;**323**:1523–30.
- 118 **Diaz O**, Iglesia R, Ferrer M, *et al*. Effects of noninvasive ventilation on pulmonary gas exchange and hemodynamics during acute hypercapnic exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1997;**156**:1840–5.
- 119 **Lightowler JV**, Wedzicha JA, Elliott MW, *et al*. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. *BMJ* 2003;**326**:185–7.
- 120 **Brochard L**, Mancebo J, Wysocki M, *et al*. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 1995;**333**:817–22.
- 121 **Bot J**, Carroll MP, Conway JH, *et al*. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. *Lancet* 1993;**341**:1555–7.
- 122 **Celikel T**, Sungur M, Ceyhan B, *et al*. Comparison of noninvasive positive pressure ventilation with standard medical therapy in hypercapnic acute respiratory failure. *Chest* 1998;**114**:1636–42.
- 123 **Plant PK**, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. *Lancet* 2000;**355**:1931–5.
- 124 **Barbe F**, Quera-Salva MA, de Lattre J, *et al*. Long-term effects of nasal intermittent positive-pressure ventilation on pulmonary function and sleep architecture in patients with neuromuscular diseases. *Chest* 1996;**110**:1179–83.
- 125 **Avdeev SN**, Tretjakov AV, Grigoriant RA, *et al*. [Study of the use of noninvasive ventilation of the lungs in acute respiratory insufficiency due exacerbation of chronic obstructive pulmonary disease]. *Anesteziol Reanimatol*, 1998;45–51.
- 126 **Dikensoy O**, Ikdag B, Filiz A, *et al*. Comparison of non-invasive ventilation and standard medical therapy in acute hypercapnic respiratory failure: a randomised controlled study at a tertiary health centre in SE Turkey. *Int J Clin Pract* 2002;**56**:85–8.
- 127 **Keenan SP**, Gregor J, Sibbald WJ, *et al*. Noninvasive positive pressure ventilation in the setting of severe, acute exacerbations of chronic obstructive

- pulmonary disease: more effective and less expensive. *Crit Care Med* 2000;**28**:2094–102.
- 128 **Plant PK**, Owen JL, Parrott S, *et al*. Cost effectiveness of ward based non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease: economic analysis of randomised controlled trial. *BMJ* 2003;**326**:956.
- 129 **Esteban A**, Anzueto A, Frutos F, *et al*. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. *JAMA* 2002;**287**:345–55.
- 130 **Nava S**, Ambrosino N, Clini E, Prato M, *et al*. Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trial. *Ann Intern Med* 1998;**128**:721–8.
- 131 **Ferrer M**, Esquinas A, Arancibia F, *et al*. Noninvasive ventilation during persistent weaning failure: a randomized controlled trial. *Am J Respir Crit Care Med* 2003;**168**:70–6.
- 132 **Esteban A**, Frutos-Vivar F, Ferguson ND, *et al*. Noninvasive positive-pressure ventilation for respiratory failure after extubation. *N Engl J Med* 2004;**350**:2452–60.
- 133 **Donner CF**, Muir JF. Selection criteria and programmes for pulmonary rehabilitation in COPD patients. Rehabilitation and Chronic Care Scientific Group of the European Respiratory Society. *Eur Respir J* 1997;**10**:744–57.
- 134 **Shepperd S**, Harwood D, Gray A, *et al*. Randomised controlled trial comparing hospital at home care with inpatient hospital care. II: Cost minimisation analysis. *BMJ* 1998;**316**:1791–6.
- 135 **Cotton MM**, Bucknall CE, Dagg KD, *et al*. Early discharge for patients with exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. *Thorax* 2000;**55**:902–6.
- 136 **Nicholson C**, Bowler S, Jackson C, *et al*. Cost comparison of hospital- and home-based treatment models for acute chronic obstructive pulmonary disease. *Aust Health Rev* 2001;**24**:181–7.
- 137 **Davies L**, Wilkinson M, Bonner S, *et al*. "Hospital at home" versus hospital care in patients with exacerbations of chronic obstructive pulmonary disease: prospective randomised controlled trial. *BMJ* 2000;**321**:1265–8.
- 138 **Ojoo JC**, Moon T, McGlone S, *et al*. Patients' and carers' preferences in two models of care for acute exacerbations of COPD: results of a randomised controlled trial. *Thorax* 2002;**57**:167–9.
- 139 **Hernandez C**, Casas A, Escarabill J, *et al*. Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients. *Eur Respir J* 2003;**21**:58–67.
- 140 **Skwarska E**, Cohen T, Skwarski KM, *et al*. Randomized controlled trial of supported discharge in patients with exacerbations of chronic obstructive pulmonary disease. *Thorax* 2002;**55**:907–12.

## LUNG ALERT .....

### Asthma and natural killer T cells

▲ Akbari O, Faul JL, Hoyte EG, *et al*. CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. *N Engl J Med* 2006;**354**:1117–29

The presence of CD4+ T helper cells in the airways of patients with asthma is well recognised, precipitating airway inflammation via cytokines such as interleukin-4, interleukin-5, and interleukin-13. Newly identified human natural killer T cells also express CD4. A subclass of this group, invariant natural killer T cells, possesses a restricted range of T cell receptors (V $\alpha$ 24-J $\alpha$ 18) which bind to glycolipid antigens presented by the class I MHC-like protein CD1d. Stimulation of such cells generates a potent cytokine response. The exact role of invariant natural killer T cells in humans is unknown. This study examined their role in asthma.

Twenty five patients were recruited, 14 with moderately severe asthma (10 taking inhaled corticosteroids), five with sarcoidosis, and six controls. None had received oral corticosteroids within 3 months of the study. Bronchoalveolar lavage (BAL), peripheral blood lymphocytes, and endobronchial biopsies were analysed.

Increased BAL lymphocyte counts with predominant CD4+ expression were seen in both patients with asthma and those with sarcoidosis. However, there were significantly more invariant natural killer T cells in those with asthma (mean 63%) than sarcoidosis (mean <1%). In asthma patients, natural killer T cells were over 100 times more abundant in BAL fluid than in peripheral blood. There was no significant difference in asthma between patients who were and were not receiving inhaled corticosteroids.

This study supports a role for invariant natural killer T cells in the pathogenesis of asthma and as a target for future therapy.

**H E Davies**

Specialist Registrar, Royal Berkshire Hospital, Reading, UK; hedavies@doctors.net.uk